Free Trial
→ Retire Comfortably with These New Monthly Income ETFs? (From Investors Alley) (Ad)tc pixel

Chugai Pharmaceutical (OTCMKTS:CHGCY) Sets New 1-Year Low - Should You Sell?

Written by MarketBeat
Updated August 12, 2025
Chugai Pharmaceutical logo with Medical background

Key Points

  • Chugai Pharmaceutical shares reached a new 52-week low on Friday, trading as low as $19.50 and closing at $20.05, down from a previous close of $25.06.
  • The company reported $0.20 earnings per share and $2.01 billion in revenue for the quarter, with a return on equity of 20.80%.
  • Chugai Pharmaceutical has a market capitalization of $65.99 billion and a PE ratio of 25.38.
  • MarketBeat previews the top five stocks to own by October 1st.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) hit a new 52-week low on Friday . The stock traded as low as $19.50 and last traded at $20.05, with a volume of 461594 shares traded. The stock had previously closed at $25.06.

Chugai Pharmaceutical Price Performance

The company has a 50-day simple moving average of $24.58 and a 200-day simple moving average of $24.70. The firm has a market cap of $68.68 billion, a PE ratio of 26.42 and a beta of 0.65.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last announced its earnings results on Thursday, July 24th. The company reported $0.20 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 20.80% and a net margin of 33.08%. The business had revenue of $2.01 billion during the quarter. As a group, equities research analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

(Get Free Report)

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

See Also

Should You Invest $1,000 in Chugai Pharmaceutical Right Now?

Before you consider Chugai Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.

While Chugai Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.